TY - JOUR AU - Li, Fengjuan AU - Kong, Xiangyue AU - Cui, Jing AU - Zhong, Baining AU - Jiang, Hongfeng AU - Wang, Lyuya AU - Wang, Yuan PY - 2026 TI - Sphingolipid metabolism disorder mediates the activation of the SPHK1/S1P/S1PR1 pathway in pathogenesis of Takayasu arteritis JO - Chinese Journal of Multiple Organ Diseases in the Elderly SN - 1671-5403 SP - 534 EP - 540 VL - 25 IS - 7 AB - ObjectiveTo investigate the role of sphingolipid metabolism disorder and its key regulatory pathways in the pathogenesis of Takayasu arteritis (TA).MethodsA total of 60 TA patients admitted to Department of Rheumatology and Immunology of Beijing Anzhen Hospital from January 2016 to December 2020 were enrolled as the TA group, while 60 age- and gender-matched healthy individuals taking routine physical examinations during the same period were selected as the health control (HC) group. Plasma samples were collected from both groups, and targeted sphingolipid metabolomics was performed to measure the levels of sphingomyelin (SM), ceramide (Cer), and sphingosine-1-phosphate (S1P). Peripheral blood mononuclear cells (PBMCs) were isolated to detect the expression levels of S1P synthase (SPHK1) and its receptor (S1PR1). Immunohistochemical staining was used to detect the protein expression of SPHK1 and S1PR1 in the arterial tissues from both groups. In vitro experiments were conducted by stimulating macrophages with the inflammatory cytokine interleukin-6 (IL-6). Quantitative real-time PCR (qPCR) and Western blotting were applied to detect the mRNA and protein expression levels of SPHK1 and S1PR1, respectively. GraphPad Prism 8 was employed for statistical analysis. Data comparison between two groups was carried out using t test or χ2 test depending on data type.ResultsCompared with the HC group, the TA group exhibited significantly higher plasma S1P levels [(3.23±0.81 vs (2.78±0.53) μmol/L, P<0.01], whereas obviously lower levels of SM and several Cer species (C16, C24) (P<0.05). The expression levels of SPHK1 and S1PR1 in PBMCs and arterial tissues were significantly increased in the TA patients than health controls (P<0.05). In vitro experiments demonstrated that IL-6 significantly induced the upregulation of SPHK1 and S1PR1 expression in macrophages at both mRNA and protein levels (P<0.05).ConclusionTA patients exhibit obvious dysregulation of sphingolipid metabolism and disruption in sphingolipid homeostasis, and elevated S1P levels are closely associated with aberrant activation of the SPHK1/S1P/S1PR1 signaling pathway. This pathway may serve as an important metabolic target for investigating the pathogenesis of TA and developing targeted therapeutic interventions. UR - https://doi.org/10.11915/j.issn.1671-5403.2026.07.108 DO - 10.11915/j.issn.1671-5403.2026.07.108